A registered study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 0
- Population
- ALL · 18 Years
- Duration
- 2024-12-12 to 2029-01-03
- Intervention
- aflibercept 8 mg
- Comparator
- Not reported
- Outcomes measured
- Mean prior treatment interval during the one-year period before study enrollment compared to the last assigned treatmen…; Change in visual acuity (VA) (Early Treatment Diabetic Retinopathy study [ETDRS]) letters) — Baseline up to 12 Months; Change in VA (ETDRS letters) — Baseline up to 24 Months; Categorical gains of ≥5 ETDRS letters — Up to 24 Months; Categorical gains of ≥10 ETDRS letters — Up to 24 Months; Categorical gains of ≥15 ETDRS letters — Up to 24 Months; Categorical losses of ≥5 ETDRS letters — Up to 24 Months; Categorical losses of ≥10 ETDRS letters — Up to 24 Months; Categorical losses of ≥15 ETDRS letters — Up to 24 Months; Proportion of patients achieving 20/40 Snellen equivalent or better — Up to 24 Months; Change in Central subfield thickness (CST) — Baseline up to 24 Months; Description of demographics — At Baseline; Descriptions of study eye characteristics — At Baseline; Treatment interval — Up to 24 Months; Missed and unscheduled visits — Up to 24 Months; Frequency of ocular adverse events (AEs) — Up to 24 Months; Frequency of non-ocular adverse events (AEs) — Up to 24 Months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.